Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AT-101: Phase I/II data

Data from the Phase I portion of the open-label, U.S. Phase

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE